Ranbaxy hones generics focus; shifts R&D to Daiichi Sankyo
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories has transferred its new drug discovery research (NDDR) activity to Daiichi Sankyo India Pharma, as part of an effort by the two firms to integrate their R&D operations.